Cisco's president Jeetu Patel mandates AI for all developers, aiming for half a dozen AI-coded products by 2026. This shift to spec-driven development sees human teams shrink, with AI agents tripling ...

Cisco's fiscal second-quarter results came in stronger than analysts had expected, but quarterly earnings guidance was in line with estimates. Networking revenue increased 21% in the period. The ...

Feb 11 (Reuters) - Cisco Systems posted quarterly adjusted gross margin below market estimates on Wednesday, as the networking equipment provider grapples with the fallout of a global memory price ...

Key abstracts on chronic myeloid leukemia (CML) treatment from the 2025 American Society of Hematology Annual Meeting and Exposition are reported by Dr Jorge Cortes from the Georgia Cancer Center in ...

Cisco Systems Inc., a bellwether stock of the dot-com technological revolution, has returned to a record after a quarter century, thanks in part to the artificial intelligence spending boom. Shares ...

Generative AI is making it even easier for attackers to exploit old and often forgotten network equipment. Replacing it takes investment, but Cisco is making the case that it’s worth it. Dubbed ...

Cisco reported better-than-expected profit and revenue in its fiscal first-quarter earnings report. The company has recorded revenue growth in four straight quarters after a stretch of four straight ...

Cisco and Nvidia are ramping up their partnership, and the latest deliverables include the new Cisco N9100 series data center switch built on Nvidia’s Spectrum-X Ethernet switch silicon. The two ...

Cisco has released security updates to address a high-severity zero-day vulnerability in Cisco IOS and IOS XE Software that is currently being exploited in attacks. Tracked as CVE-2025-20352, the flaw ...

Cisco plans to cut more than 150 employees as part of a new round of layoffs, with the cuts coming days after CEO Chuck Robbins said the company would not be slicing jobs in favor of AI. The latest ...

Chronic myeloid leukemia (CML) is a hematopoietic malignancy characterized by BCR-ABL1 gene fusion. The immune microenvironment, implicated in relapse and drug resistance, poses significant challenges ...